IRADIMED CORPORATION IRMD R2KR3KPHARMA

Q: What is the current share price of IRADIMED CORPORATION (IRMD)?

As of 2026-09-07 16:24 PDT, IRADIMED CORPORATION (IRMD) trades at $83.45 on NasdaqGM. Its 52-week range is $67.62 to $104.63.

Q: What is the market capitalisation of IRMD?

IRADIMED CORPORATION (IRMD) has a market capitalisation of $1.07B on NasdaqGM.

Q: What is the P/E ratio of IRMD?

IRMD trades at a trailing price-to-earnings (P/E) ratio of 46.62. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 12.00.

Q: Does IRMD pay a dividend?

IRADIMED CORPORATION (IRMD) currently offers a dividend yield of 0.88%.

Q: What is the return on equity (ROE) of IRMD?

IRMD has a return on equity (ROE) of 23.52%. Its return on capital employed (ROCE) is 26.52%.

Q: Is IRMD a good stock to buy?

This page provides a data-driven analysis of IRADIMED CORPORATION (IRMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Healthcare · Medical Devices · United States

https://www.iradimed.com

Company Profile ↓

$83.45

+19.17% 1Y

Mkt Cap$1.07B

P/E46.62

P/B12.00

Div. Yield0.88%

52W High$104.63

52W Low$67.62

Book Value$7.71

EPS (TTM)$1.79

Company Overview

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 23.5%, reflecting efficient use of shareholder capital.

Healthy Capital Returns

Return on capital employed stands at 26.5%.

Consistent Profit Growth

Net profit has compounded at 25.0% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 19.9% CAGR over the past five years.

Healthy Margins

Maintains a net profit margin of 26.7%.

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.00.

Recent Developments

Dec 2025 Revenue of $83.81M (+14.4% YoY); net profit $22.48M.
Trailing 12 Months Year-on-year growth — revenue +0.3%, earnings -9.3%.
5-Year Trend Long-term compounding — revenue CAGR 19.9%, profit CAGR 25.0%.

Growth & Price Performance

Compounded Sales Growth

5 Years:	19.94%
1 Year:	0.30%

Compounded Profit Growth

5 Years:	24.97%
1 Year:	-9.30%

Stock Price Performance

1 Year:	+19.17%
6 Months:	-15.08%
3 Months:	-10.13%
1 Month:	-8.30%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bearish

52-Week Range 43% of range

$67.62 $104.63

Trend Signals

Price vs 50-DMABelow
Price vs 200-DMABelow
RSI (14)29.46 · Oversold

Price Performance

1M-8.30%

3M-10.13%

6M-15.08%

1Y+19.17%

Valuation vs Sector

P/E of 46.62 is above the sector median of 25.17 — pricier than peers.

Auto-generated from price history and fundamentals; not investment advice.

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Period: Metric:

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

Strong return on equity of 23.5%.
Healthy ROCE of 26.5%.
Excellent profit margin of 26.7%.
Compounding revenue at 19.9% over 5 years.
Profit CAGR of 25.0% over 5 years.
Generates positive free cash flow.

CONS

In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

Valuation

Stock P/E

46.62

Industry PE

25.17

Forward P/E

34.63

PEG Ratio

Book Value

$7.71

Price to Book

12.00

P/S

13.70

EV/EBITDA

38.50

Dividend Yield

0.88%

Growth (CAGR)

Revenue 5Y

19.94%

Profit 5Y

24.97%

Revenue (YoY)

0.30%

Earnings (YoY)

-9.30%

Profitability & Returns

ROCE

26.52%

ROE

23.52%

ROA

15.56%

Profit Margin

26.70%

Op Margin

31.23%

Gross Margin

75.86%

EPS (Latest Qtr)

$0.41

EPS (TTM)

$1.79

Balance Sheet & Liquidity

Debt/Equity

0.00

Quick Ratio

7.89

Current Ratio

9.46

Debt

Total Assets

$114.97M

Current Assets

$86.42M

Working Capital

$71.02M

Ownership

Promoter Holding

35.19%

Chg in Prom Hold

-0.01%

FII / Inst Holding

62.75%

Chg in FII Hold

-0.06%

Financial Snapshot

Enterprise Value

$1.07B

Total Revenue (TTM)

$86.34M

EBITDA

$29.18M

Free Cash Flow

$16.20M

Operating Cash Flow

$27.14M

Shares Outstanding

12.79M

Gross Margin

75.86%

Payout Ratio

41.34%

Peer comparison

Peer companies in the same sector (Healthcare).

#	Name	CMP $	P/E	Mkt Cap	Div Yld %	ROCE %	ROE %	Rev CAGR 5Y %	Profit CAGR 5Y %
1	IRMD IRADIMED CORPORATION R2KR3KPHARMA	83.45	46.62	$1.07B	0.88%	26.52%	23.52%	19.94%	24.97%
2	LLY Eli Lilly and Company SPXR3KPHARMA	1,149.36	38.57	$1.02T	0.58%	-	102.29%	7.20%	11.41%
3	JNJ Johnson & Johnson SPXR3KPHARMA	275.23	31.97	$663.28B	2.09%	14.88%	25.74%	2.43%	4.76%
4	ABBV AbbVie Inc. SPXR3KPHARMA	256.46	72.45	$453.19B	2.84%	10.47%	-129.24%	1.75%	-29.06%
5	MRK Merck & Co., Inc. SPXR3KPHARMA	150.33	120.26	$371.29B	2.65%	-	34.70%	5.64%	10.01%
6	UNH UnitedHealth Group Incorporated SPXR3KPHARMA	397.14	25.54	$356.47B	2.33%	9.74%	14.15%	10.40%	5.43%
7	NVS Novartis AG PHARMA	159.99	24.20	$304.10B	3.03%	21.09%	30.35%	9.25%	26.22%
8	AZN AstraZeneca PLC NDXPHARMA	162.70	24.36	$252.33B	1.98%	15.97%	21.96%	9.82%	45.96%
9	AMGN Amgen Inc. NDXSPXR3KPHARMA	437.23	27.14	$235.98B	2.49%	13.95%	91.47%	5.51%	5.55%

Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric	Mar 2014	Jun 2014	Sep 2014	Mar 2015	Jun 2015	Sep 2015	Mar 2016	Jun 2016	Sep 2016	Mar 2017	Jun 2017	Sep 2017	Mar 2018	Jun 2018	Sep 2018	Mar 2019	Jun 2019	Sep 2019	Mar 2020	Jun 2020	Sep 2020	Mar 2021	Jun 2021	Sep 2021	Mar 2022	Jun 2022	Sep 2022	Mar 2023	Jun 2023	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	-	-	-	-	-	-	-	-	-	-	5.52M	5.69M	7.11M	7.38M	7.61M	8.44M	9.23M	9.96M	8.68M	6.79M	7.70M	9.22M	9.81M	10.91M	12.31M	12.72M	13.41M	15.48M	16.13M	16.50M	17.60M	17.93M	18.33M	-	19.51M	20.41M	21.20M	22.69M	21.98M	20.47M
Cost of Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4.67M	4.45M	4.71M	5.66M	5.17M	-
Gross Profit	2.90M	3.83M	2.85M	5.66M	6.19M	6.60M	7.26M	8.13M	6.27M	3.77M	4.29M	4.38M	5.42M	5.67M	5.79M	6.39M	7.37M	7.80M	6.46M	4.93M	5.74M	7.06M	7.33M	8.41M	9.38M	10.14M	10.54M	11.72M	12.19M	12.84M	13.39M	14.01M	14.19M	-	14.84M	15.95M	16.49M	17.03M	16.81M	15.16M
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	9.41M	9.17M	9.66M	9.94M	9.58M	-
Operating Income	824.08K	1.61M	406.31K	2.26M	2.69M	3.20M	3.48M	3.34M	2.59M	-238.38K	327.57K	196.06K	1.09M	1.68M	1.45M	1.51M	2.38M	2.52M	737.24K	-2.93M	784.76K	1.78M	1.84M	3.09M	3.07M	4.17M	4.13M	4.01M	4.96M	5.91M	4.75M	5.63M	5.79M	-	5.43M	6.79M	6.83M	7.09M	7.24M	6.39M
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.63M	7.00M	7.22M	7.47M	7.69M	-
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	5.95M	7.33M	7.30M	7.79M	7.77M	-
Tax Provision	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.26M	1.55M	1.72M	1.35M	1.95M	-
Net Income	523.37K	1.02M	237.36K	1.49M	1.77M	1.87M	2.28M	2.23M	1.56M	-233.34K	357.07K	192.39K	841.20K	1.35M	2.40M	1.85M	2.09M	2.45M	1.77M	-2.11M	1.07M	1.39M	1.47M	2.58M	2.49M	3.24M	3.43M	3.41M	4.18M	5.07M	4.14M	4.90M	5.05M	-	4.69M	5.77M	5.58M	6.44M	5.82M	5.22M
Diluted EPS	0.06	0.11	0.02	0.12	0.15	0.15	0.19	0.19	0.13	-0.02	0.03	0.02	0.07	0.11	0.20	0.15	0.17	0.20	0.14	-0.17	0.09	0.11	0.12	0.20	0.20	0.26	0.27	0.27	0.33	0.40	0.32	0.38	0.40	-	0.37	0.45	0.43	0.50	0.45	0.41
R&D Expense	224.30K	225.50K	303.46K	342.30K	403.45K	518.56K	234.34K	291.82K	457.13K	541.29K	449.01K	382.70K	379.83K	395.99K	373.58K	352.57K	331.31K	369.53K	430.28K	482.65K	476.88K	475.82K	453.68K	480.70K	519.10K	662.60K	491.64K	3.00M	961.95K	452.56K	821.00K	801.13K	639.47K	-	624.00K	877.36K	674.36K	-	956.00K	657.00K

Profit & Loss (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Revenue	11.34M	15.65M	31.59M	32.50M	23.08M	30.44M	38.52M	31.72M	-	53.30M	65.56M	73.24M	83.81M
Cost of Revenue	-	-	-	-	-	-	-	-	-	12.02M	15.40M	16.89M	19.49M
Gross Profit	8.49M	12.25M	25.75M	26.34M	17.51M	23.23M	29.70M	23.57M	-	41.28M	50.16M	56.35M	64.32M
Operating Expenses	-	-	-	-	-	-	-	-	-	25.65M	30.12M	34.38M	38.18M
Operating Income	2.79M	3.07M	11.51M	10.92M	1.29M	6.00M	8.65M	-756.09K	-	15.63M	20.04M	21.96M	26.15M
EBITDA	-	-	-	-	-	-	-	-	-	16.30M	20.80M	22.78M	27.31M
Interest Expense	-	-	-	-	-	-	-	-	-	-	-	-	-
Pretax Income	-	-	-	-	-	-	-	-	-	16.18M	21.74M	24.27M	28.36M
Tax Provision	-	-	-	-	-	-	-	-	-	3.35M	4.55M	5.04M	5.88M
Net Income	1.94M	2.05M	7.53M	7.21M	499.76K	6.30M	9.63M	1.37M	-	12.83M	17.19M	19.23M	22.48M
Diluted EPS	0.22	0.20	0.60	0.60	0.04	0.52	0.78	0.11	-	1.02	1.35	1.50	1.75
R&D Expense	1.01M	1.07M	1.76M	1.35M	1.72M	1.52M	1.43M	1.90M	1.91M	2.28M	2.86M	2.83M	2.98M

Balance Sheet (Annual)

Figures in USD.

Metric	Dec 2012	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Assets	-	6.99M	23.31M	35.24M	37.19M	39.01M	48.44M	66.73M	71.07M	-	85.51M	92.16M	98.33M	108.78M
Current Assets	-	-	-	-	-	-	-	-	-	-	77.49M	76.00M	75.24M	81.20M
Cash & Equivalents	1.70M	2.46M	9.45M	19.37M	17.71M	18.21M	28.03M	43.48M	50.07M	-	57.96M	49.76M	52.23M	51.16M
Inventory	-	-	-	-	-	-	-	-	-	-	5.37M	12.82M	10.40M	11.62M
Receivables	-	-	-	-	-	-	-	-	-	-	13.27M	12.22M	10.56M	13.67M
Total Liabilities	-	1.56M	2.42M	3.31M	5.31M	6.08M	6.50M	11.20M	9.68M	-	11.84M	20.74M	11.51M	14.16M
Current Liabilities	-	1.45M	2.28M	2.89M	3.66M	4.08M	4.69M	5.86M	4.92M	-	8.55M	16.33M	8.51M	10.18M
Long Term Debt	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Debt	-	-	-	-	-	-	-	-	-	-	2.21M	2.04M	2.00K	0
Total Equity	3.22M	5.42M	20.89M	31.93M	31.89M	32.93M	41.95M	55.52M	61.38M	-	73.67M	71.42M	86.82M	94.62M
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	12.59M	12.66M	12.71M	12.78M

Cash Flows (Annual)

Figures in USD.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Operating Cash Flow	-	-	7.65M	9.41M	3.42M	7.38M	10.23M	5.82M	-	10.04M	13.47M	25.62M	24.95M
Investing Cash Flow	-196.75K	-8.30M	-61.47K	-1.94M	-1.02M	1.52M	3.20M	246.97K	-	-1.37M	-8.01M	-8.82M	-8.42M
Financing Cash Flow	-	-	2.33M	-9.12M	-1.90M	929.87K	2.02M	522.48K	-	-12.71M	-13.66M	-14.34M	-17.60M
Capital Expenditure	-163.18K	-583.98K	-298.72K	-780.81K	-775.57K	-228.31K	-368.28K	-443.00K	-	-1.87M	-8.01M	-8.82M	-8.42M
Free Cash Flow	-	-	7.35M	8.63M	2.64M	7.15M	9.86M	5.37M	-	8.17M	5.46M	16.81M	16.53M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-4.04M	-8.20M	2.47M	-1.07M
Share Buybacks	-	-	-	9.97M	1.82M	-	-	-	-	-	-	-	-
Dividends Paid	-	-	-	-	-	-	-	-	-	12.56M	13.22M	13.68M	15.04M

Ratios (Annual)

Figures in %.

Metric	Dec 2013	Dec 2014	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Gross Margin %	74.8%	78.3%	81.5%	81.1%	75.9%	76.3%	77.1%	74.3%	-	77.4%	76.5%	76.9%	76.7%
Operating Margin %	24.6%	19.6%	36.4%	33.6%	5.6%	19.7%	22.5%	-2.4%	-	29.3%	30.6%	30.0%	31.2%
Net Margin %	17.1%	13.1%	23.8%	22.2%	2.2%	20.7%	25.0%	4.3%	-	24.1%	26.2%	26.3%	26.8%
ROE %	35.7%	9.8%	23.6%	22.6%	1.5%	15.0%	17.3%	2.2%	-	17.4%	24.1%	22.2%	23.8%
ROCE %	50.4%	14.6%	35.6%	32.6%	3.7%	13.7%	14.2%	-1.1%	-	20.3%	26.4%	24.5%	26.5%

Shareholding Pattern

Insiders

35.19%

Institutions

62.75%

Public Float

96.81%

Top Institutional Holders

#	Holder	% Held	Shares	Value
1	Blackrock Inc.	7.57%	967.83K	$84.27M
2	Kayne Anderson Rudnick Investment Management LLC	3.10%	396.98K	$34.57M
3	Renaissance Technologies, LLC	3.08%	394.41K	$34.34M
4	Copeland Capital Management, LLC	3.06%	391.86K	$34.12M
5	Vanguard Capital Management LLC	2.85%	364.94K	$31.78M
6	T. Rowe Price Investment Management, Inc.	2.49%	318.68K	$27.75M
7	Geode Capital Management, LLC	2.27%	290.11K	$25.26M
8	Nine Ten Capital Management LLC	2.01%	256.56K	$22.34M
9	Dimensional Fund Advisors LP	1.79%	229.34K	$19.97M
10	State Street Corporation	1.73%	221.51K	$19.29M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for IRMD

Google News hu, 03 Sep 2026

IRADIMED (NASDAQ: IRMD) director flags 1,102 RSU shares for possible sale - Stock Titan

<a href="https://news.google.com/rss/articles/CBMilAFBVV95cUxPQl9uS29pZWdUbldrZWdNcXZfeHdTOEwycXZyRzFtR1kzbFFZWEowR3ZsSV9NOWdZNUVpbVphdDY3alRMOU5VNGZzXzRvVC1mdzMwOUVmLVpQWnFVMWdjVEtMWTZpcnN4N1NjSHhsc21oQ0NJMF9oUjFUM3lkbUtVMTRMb3FuMi1NNHFNcT…

Google News Sat, 05 Sep 2026

iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100 - GuruFocus

<a href="https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYW1MRGtsX2hUYndUWU84MEpycU15OGxyeVRYTmRnZExLN1BOM1A2N3JJTjUtUXZtcTNhUGE2WE9YNnB4N0hrQjZTSTh2WVlaLWVzZ2JNbXdQMm9Wb2htMkZzVTNVVHZ6R014UG82ekZYanZTUW4zZ25wN0hWTklLOVNTRzN6NXF1b3Bfdj…

Google News Sun, 02 Aug 2026

IRADIMED (IRMD) Stock Drops As 3870 Ramp Cuts Gross Margin - simplywall.st

<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNU1pjeFdHLTRIVTc3eW9XTmVqQ1NMaDZlM1BsaEozdWpqNEdBTTJGWTRtN19yZ2ZxcDV5eVpyTklpTjVXc1JvLW1qN2tISTZkTnlsMEFhUUswcm95ZUcwRTVsa3dZRWF6ZHJGV3pBZGVFTW1nZ0ZrbnFCckNXT1AtMmlfNTFfd1RHQy1oOD…

Google News Mon, 27 Jul 2026

Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxOQ1BPdTBQM1B0TnVoQ2JHOE5rQTgtajhZRnZ6dkNJdHozQTNaWW0xc0NVTXc3Q0VCQjZ0RU1MUUtQSkI5MjlBYmVWS2NtQUlKRFVRZDJwZEFfOVBmVEhoT3F2X1ZrYlA0bndvZDJjeDNTbGc2Vmtjdm92U3F0MzU5RERSQWFBZFZzQjV1WG…

Google News Sat, 05 Sep 2026

IRMD stock trades steadily as iRhythm Technologies posts strong Q2 2026 growth - ad-hoc-news.de

<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxPZkgwSGtUZlNWVmkxenl4aFVDOFdXZ1R1cjJxbm1mazd2aDNMVnQzTEtOTWpzaWVLS2FxdGV4N3dYeHJfRGxFSnc4WHJqTzRYMlR1MHpJdDhYQjQxYllkclJlXzZ6VDY1aGpWUFhMU3RkUldtQW5rY3l2Q2tLeW0yVlFrSkZoVkNTUElPZG…

Google News Fri, 01 May 2026

IRADIMED ($IRMD) Releases Q1 2026 Earnings - quiverquant.com

<a href="https://news.google.com/rss/articles/CBMigAFBVV95cUxNLUNIWjVjVXFWbWlObzFIeWNaZ0VQcHVYRmFpbklFNjZlR1FvNGdGby00dVUwbnA1TlUzUG1hMWp6UUFKUUJ1Z3poRDRFQVVXOG01U3Ria1FjSEVYRUR6SkRfS0V0NnNWWlk3dW5VRFFLRTduSmcteUlfanIxS2FkYQ?oc=5" target="_…

IRMD — Frequently Asked Questions

What is the current share price of IRADIMED CORPORATION (IRMD)?

As of 2026-09-07 16:24 PDT, IRADIMED CORPORATION (IRMD) trades at $83.45 on NasdaqGM. Its 52-week range is $67.62 to $104.63.

What is the market capitalisation of IRMD?

IRADIMED CORPORATION (IRMD) has a market capitalisation of $1.07B on NasdaqGM.

What is the P/E ratio of IRMD?

IRMD trades at a trailing price-to-earnings (P/E) ratio of 46.62. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 12.00.

Does IRMD pay a dividend?

IRADIMED CORPORATION (IRMD) currently offers a dividend yield of 0.88%.

What is the return on equity (ROE) of IRMD?

IRMD has a return on equity (ROE) of 23.52%. Its return on capital employed (ROCE) is 26.52%.

Is IRMD a good stock to buy?

This page provides a data-driven analysis of IRADIMED CORPORATION (IRMD), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks

IRADIMED CORPORATION IRMD R2KR3KPHARMA

Company Overview

Why Investors Should Care

Recent Developments

Growth & Price Performance

Compounded Sales Growth

Compounded Profit Growth

Stock Price Performance

Price Chart

Technical Trend

Fundamental Growth Charts

PROS

CONS

Valuation

Growth (CAGR)

Profitability & Returns

Balance Sheet & Liquidity

Ownership

Financial Snapshot

Peer comparison

Quarterly Results

Profit & Loss (Annual)

Balance Sheet (Annual)

Cash Flows (Annual)

Ratios (Annual)

Shareholding Pattern

Top Institutional Holders

Analyst View

Latest News

IRADIMED (NASDAQ: IRMD) director flags 1,102 RSU shares for possible sale - Stock Titan

iRadimed Corp (IRMD) Stock Down 3.8% but Still Overvalued -- GF Score: 92/100 - GuruFocus

IRADIMED (IRMD) Stock Drops As 3870 Ramp Cuts Gross Margin - simplywall.st

Iradimed Corporation (IRMD) Sales Reflects The Fund’s Valuation and Sizing Discipline - Yahoo Finance

IRMD stock trades steadily as iRhythm Technologies posts strong Q2 2026 growth - ad-hoc-news.de

IRADIMED ($IRMD) Releases Q1 2026 Earnings - quiverquant.com

IRMD — Frequently Asked Questions

What is the current share price of IRADIMED CORPORATION (IRMD)?

What is the market capitalisation of IRMD?

What is the P/E ratio of IRMD?

Does IRMD pay a dividend?

What is the return on equity (ROE) of IRMD?

Is IRMD a good stock to buy?

Explore More